白蛋白紫杉醇联合吉西他滨在局部晚期不可切除胰腺癌中优于吉西他滨单药:GISCAD II期随机试验
该II期随机试验纳入124例局部晚期不可切除胰腺癌患者,比较白蛋白紫杉醇联合吉西他滨与吉西他滨单药的疗效。主要终点为三周期化疗后疾病进展率,联合组显著低于单药组(25.4% vs 45.6%,P=0.01),且应答率、无进展生存期和总生存期均有改善。这是首个在该人群中证实联合化疗优于吉西他滨单药的随机试验。
要点
- 白蛋白紫杉醇联合吉西他滨较吉西他滨单药显著降低三周期后疾病进展率。
- 联合组6个月远处转移率更低,应答率更高,无进展生存期和总生存期延长。
- 该方案为局部晚期不可切除胰腺癌提供了优于单药吉西他滨的联合化疗选择。
核心结论
- 白蛋白紫杉醇联合吉西他滨较吉西他滨单药降低局部晚期不可切除胰腺癌三周期化疗后进展率,尤其减少远处转移,并改善无进展生存期。
研究设计与样本
- II期随机试验,1:1随机分配124例局部晚期不可切除胰腺癌患者,比较白蛋白紫杉醇联合吉西他滨与吉西他滨单药。
主要发现
- 三周期化疗后疾病进展率联合组25.4%,单药组45.6%(P=0.01)。
- 6个月时单药组35.6%患者出现转移,联合组20.8%。
- 应答率单药组5.3%,联合组27%;中位无进展生存期单药组4个月,联合组7个月;中位总生存期单药组10.6个月,联合组12.7个月。
- 单药组一例患者在治疗期间死于卒中。
关键数值与推荐
- 吉西他滨单药方案:1000 mg/m2,第1、8、15天,每28天重复。
- 联合方案:白蛋白紫杉醇125 mg/m2联合吉西他滨1000 mg/m2,均第1、8、15天,每28天重复。
- 主要终点为三周期化疗后疾病进展率;次要终点包括无进展生存期、总生存期和应答率。
临床怎么用
- 对于局部晚期不可切除胰腺癌,可考虑白蛋白紫杉醇联合吉西他滨作为优于吉西他滨单药的联合化疗方案。
- 联合方案可能尤其有助于减少远处转移,但需结合患者体能状态选择。
局限性
- 为II期随机试验,样本量124例,结论需III期试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of combination chemotherapy has not yet been established in unresectable locally advanced pancreatic cancer (LAPC) lacking dedicated randomized trials. METHODS: This phase II trial tested the efficacy of Nab-paclitaxel (NAB-P)/Gemcitabine (G) versus G alone. Patients were randomized, 1:1 to G 1000 mg/m2 on days 1, 8 and 15 every 28 days versus NAB-P 125 mg/m2 on days 1, 8 and 15 every 28 days plus G 1000 mg/m2 on days 1, 8 and 15 every 28 days. Disease progression rate after three cycles of chemotherapy was the primary end-point. Progression-free survival (PFS), overall survival (OS) and response rate were secondary end-points. FINDINGS: A total of124 patients were enrolled. The study showed a reduction of a progressive disease from 45.6% with G to 25.4% with NAB-P/G (P = 0.01) at 3 months. Noteworthy, at 6 months in the G arm, 35.6% of patients present a metastatic spread versus 20.8% in the NAB/G arm. The response rate was 5.3% in the G arm and 27% in the NAB/G arm. Median PFS was 4 months for the G arm and 7 months for the NAB-P/G arm. Median OS was 10.6 in the G arm and 12.7 months in the NAB-P/G arm. One patient died during treatment with G due to a stroke. INTERPRETATION: NAB-P/G reduced the rate of LAPC patients progressing after three cycles of chemotherapy compared with G, especially in terms of distant relapses. It positively affects PFS. To the best of our knowledge, this is the first randomized trial providing evidence that combination chemotherapy is superior to gemcitabine alone in this setting. CLINICALTRIALS. GOV IDENTIFIER: NCT02043730.
引用
- Cascinu S, Berardi R, Bianco R, et al. Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial. Eur J Cancer. 2021. PMID: 33812334. doi:10.1016/j.ejca.2021.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。